Income Statement
LYELL IMMUNOPHARMA, INC.
LYEL
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
0.04 | 0.06 | 0.13 | 84.68 | 10.65 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
0.04 | 0.06 | 0.13 | 84.68 | 10.65 |
|
Operating Expenses
|
269.44 | 358.82 | 247.14 | 271.74 | 225.43 |
|
Research & Development
|
158.68 | 171.60 | 182.95 | 159.19 | 138.69 |
|
Selling, General & Administrative
|
45.14 | 52.04 | 66.98 | 117.31 | 89.06 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-269.40 | -358.76 | -247.01 | -187.06 | -214.78 |
|
Non-Operating Income
|
-5.04 | 15.76 | 12.38 | 3.94 | -35.44 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
-18.12 | 4.69 | 1.85 | 1.89 | -0.16 |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-274.45 | -342.99 | -234.63 | -183.12 | -250.22 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-257.87 | -339.12 | -226.76 | -169.04 | -201.15 |
|
Earnings Per Share (Basic)
|
-16.06 | -1.31 | -0.93 | 0.34 | -1.84 |
|
Diluted EPS
|
-16.06 | -1.31 | -0.93 | 0.34 | -1.84 |
|
Weighted Average Shares
|
17.09 | 261.48 | 250.98 | 247.08 | 0.14 |
|
Diluted Weighted Avg Shares
|
17.09 | 261.48 | 250.98 | 247.08 | 0.14 |
|
Comprehensive Income
|
-274.50 | -342.61 | -227.13 | -189.09 | -252.10 |